The European Medicines Agency’s human medicines committee recommended approval of Moderna’s mCombriax, a combined seasonal influenza and COVID‑19 mRNA vaccine for adults aged 50 and over. The CHMP opinion, announced after review of immune‑response and standalone flu component data, moves the shot closer to formal EU authorization pending European Commission sign‑off. Moderna CEO Stéphane Bancel called the recommendation an important milestone; the company has faced a more contested path with U.S. regulators, where additional comparator data have been required. The CHMP decision could let Moderna commercialize the first flu/COVID combination vaccine in Europe and adds regulatory momentum amid industry efforts to streamline respiratory vaccination. Regulatory acceptance in Europe contrasts with continued uncertainty at the FDA and may alter global roll‑out and trial strategy for combination respiratory vaccines.